Navigation Links
Trubion Announces Preliminary Analysis of Phase IIb Results With TRU-015 in Rheumatoid Arthritis
Date:9/10/2007

Results Show Improvements in RA Signs and Symptoms Compared to Placebo

SEATTLE, Sept. 10 /PRNewswire-FirstCall/ -- Trubion Pharmaceuticals Inc. (Nasdaq: TRBN) today announced preliminary analysis of results from a Phase IIb randomized, double-blind, placebo-controlled, multicenter clinical trial of its TRU-015 product candidate for rheumatoid arthritis (RA). The results indicated that Trubion's TRU-015 product candidate, at well-tolerated dosages, provided statistically significant improvements in RA signs and symptoms compared to placebo at 24 weeks. Trubion is co-developing TRU-015 with Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), for the treatment of rheumatoid arthritis.

TRU-015 Phase IIb Clinical Trial Protocol and Results

The Phase IIb randomized, double-blind, placebo-controlled, multicenter clinical trial included 276 patients with rheumatoid arthritis who were also receiving methotrexate as background therapy. Patients in the Phase IIb study were randomized evenly into five groups that received either placebo, 200 mg, 400 mg, 800 mg or 1600 mg of TRU-015.

The study was designed to evaluate the safety and efficacy of a single intravenous infusion of TRU-015 compared to placebo for a 24-week period, with a primary endpoint of improvement on the Disease Activity Score (DAS)-28 scale at 12 weeks, and secondary endpoints including response rates at 24 weeks using American College of Rheumatology (ACR) criteria.

Preliminary analysis i
'/>"/>

SOURCE Trubion Pharmaceuticals Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
2. Sygnis Pharma AG announces date for presentation of clinical results
3. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
6. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
7. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
9. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
10. Protox Announces Positive Clinical Data from Prostate Cancer Study
11. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... , Jan. 23, 2015 Tianyin Pharmaceutical Inc. (NYSE ... specializes in the development and sale of patented biopharmaceutical ... active pharmaceutical ingredients (API) today announced the business and ... operation. 1. Following the September 2014 JCM ...
(Date:1/22/2015)... Therapeutics Inc. (OTCQX:PVTTF; CSE:PVO), ("Pivotal" or the "Company"), a specialty ... disease and overall health is pleased to provide you with ... outlook for 2015 from the CEO, Mr. Eugene Bortoluzzi ... like to take this opportunity to share with you the ...
(Date:1/22/2015)... , Jan. 22, 2015 Research and Markets ... the "Infectious Disease Diagnostics Market by Product, Application, ... report to their offering. , The infectious ... of 7.9% to reach $18,156.2 million by 2019 from ...
Breaking Medicine Technology:TPI's JCM Updates on Import Registration for International Clients 2TPI's JCM Updates on Import Registration for International Clients 3TPI's JCM Updates on Import Registration for International Clients 4Pivotal Therapeutics: Year in Review and CEO Update 2Pivotal Therapeutics: Year in Review and CEO Update 3Pivotal Therapeutics: Year in Review and CEO Update 4Pivotal Therapeutics: Year in Review and CEO Update 5Pivotal Therapeutics: Year in Review and CEO Update 6Pivotal Therapeutics: Year in Review and CEO Update 7Global Infectious Disease Diagnostics (Instruments, Reagents, Services, Software) Market - Forecast to 2019 2Global Infectious Disease Diagnostics (Instruments, Reagents, Services, Software) Market - Forecast to 2019 3
... NEW ORLEANS , May 3 ... developing novel catheter-mounted digital imaging devices, today announced five ... Retroscope® during colonoscopy procedures increases detection of adenomas and ... years of experience, were able to detect adenomas of ...
... Questcor Pharmaceuticals, Inc . (Nasdaq: QCOR ) today announced that it will ... Panel meeting on Monday, May 10, 2010 at ... Don Bailey , President and Chief Executive Officer; Steve Cartt ... Chief Science Officer; and Dr. Jason Zielonka , Senior Vice President and ...
Cached Medicine Technology:Third Eye(R) Retroscope(R) Demonstrates Improved Adenoma Detection 2Third Eye(R) Retroscope(R) Demonstrates Improved Adenoma Detection 3Third Eye(R) Retroscope(R) Demonstrates Improved Adenoma Detection 4Third Eye(R) Retroscope(R) Demonstrates Improved Adenoma Detection 5Third Eye(R) Retroscope(R) Demonstrates Improved Adenoma Detection 6Questcor to Discuss Results From FDA Panel Meeting 2
(Date:1/22/2015)... (PRWEB) January 22, 2015 The Incredible Bulk ... Ben Pakulski to increase lean muscle by up to 30lbs ... caught the attention of HealthyandFitZone.com’s Stan Stevenson, prompting an investigative ... it is a step-by-step, scientific diet formula that allows the ...
(Date:1/22/2015)... AngelWeddingDress, the premier women’s dress supplier, ... dresses. View website of AngelWeddingDress.com to find ... wedding dresses online for a bridal party. AngelWeddingDress offers ... for them. Its maternity wedding dresses are specially designed ...
(Date:1/22/2015)... Dallas, TX (PRWEB) January 22, 2015 ... the issue of experience and person-centeredness in the long-term ... moving towards action across the continuum. The paper, “The ... the Continuum,” engages perspectives and practices of the patient, ...
(Date:1/22/2015)... For over 20 years, Dr. David Cruz of ... area has treated just about every type of injury that ... And for those same twenty-plus years, the team at Doctors ... with the best possible doctor. With the combined breadth ...
(Date:1/22/2015)... 2015 A study recently published ... journal Medicine & Science in Sports & Exercise ... help reduce gastrointestinal (GI) problems associated with physical ... in the double-blind, placebo-controlled study took 10 grams ...
Breaking Medicine News(10 mins):Health News:The Incredible Bulk: Review Examining Ben Pakulski’s Brand New Bulking Muscle Building Diet Program Released 2Health News:AngelWeddingDress Has Recently Released Its Collection Of 2015 Maternity Wedding Dresses 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 3Health News:Industry Leading Chiropractor in Oceanside Joins the Doctors on Liens Network 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 3
... HIV/AIDS Atlas , , WASHINGTON, June 22 The ... ( http://www.MapHIV.org ) that highlights the ... States. The Atlas makes information on HIV/AIDS prevalence rates ... a comprehensive picture of the varying intensity of the epidemic ...
... to small increased chances of trouble, research shows , MONDAY, ... double the risk of kidney stones, though the actual odds ... Roux-en-Y, the most common type of gastric bypass surgery, may ... developing the urinary tract disorder usually caused by oxalate in ...
... 22 MUSCLEPHARM(R) LLC, the rising star of the ... product launch through each of Vitamin Shoppe,s 400+ locations ... this nationwide launch of our entire line of products," ... available to athletes in nearly every neighborhood across the ...
... successful completion of the MyCopy pilot project, the specialist ... extended this eBook service to all academic libraries in ... Collections. All registered library patrons will be able to ... for their personal use by clicking on a button ...
... , , HARRISBURG, Pa., June 22 In an ... use on their unborn babies, the Pennsylvania Department of Health ... a new smoking cessation campaign to target the 28 percent ... state. , , "More than one-quarter of expectant ...
... Supreme Court Confirmation Hearings Consider Impact on All Pregnant Women ... for Pregnant Women (NAPW) today released to the public a ... Committee of the United States Senate requesting that the Committee ... Is there a point in pregnancy when you believe ...
Cached Medicine News:Health News:MapHIV.org Shows California's San Francisco County Seriously Impacted by HIV 2Health News:MapHIV.org Shows California's San Francisco County Seriously Impacted by HIV 3Health News:Common Weight-Loss Surgery May Double Risk of Kidney Stones 2Health News:MUSCLEPHARM Products Hit Vitamin Shoppe Shelves With a Bang! 2Health News:Springer launches MyCopy service for eBook users 2Health News:State Launches New Campaign to Help Pregnant Smokers Go Tobacco-Free 2Health News:Dismantling Roe v. Wade Would Affect All Pregnant Women 2Health News:Dismantling Roe v. Wade Would Affect All Pregnant Women 3
For the quantitative determination of uric acid in serum....
The assay kit is for determination of uric acid in serum or urine. Wavelength: 600 nm. Linear range: up to 80 mg/dL....
For the quantitative determination of Uric Acid in serum. Linearity: 25 mg/dl....
... A fully automated, random ... over 50 assays available ... tumor marker, therapeutic drug, ... testing can be performed ...
Medicine Products: